HALO Air Ambulance expands fleet of helicopters
It's a resource nobody wants to use, but when they do need it, it's the most welcome sight in the world.
'Very grateful and will always be grateful for HALO and what they've done for my family,' said Aaron Fleming, whose daughter was rescued by a HALO crew in 2020 when on a ski trip in Elkwater.
'(HALO made sure) that we were able to continue planning family vacations rather than a family funeral.'
He says his daughter, who was 16 years old at the time, hit a tree when on the slopes and, if it wasn't for HALO, things would have turned out drastically different.
'She would have died if it wasn't for HALO.'
Story continues below advertisement
His daughter's rescue came during a rough year for the air ambulance as they were on the brink of shutting down entirely.
'In 2020, when the announcement was that they would potentially have to close their doors due to no funding, it was something that tugged at my heartstrings,' said Fleming.
He had, earlier in the year, made a significant donation to HALO, believing it was too valuable of a resource to risk losing, but when HALO needed him, he and his family needed them.
Get daily National news
Get the day's top news, political, economic, and current affairs headlines, delivered to your inbox once a day. Sign up for daily National newsletter Sign Up
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy
'HALO saved her life when we were trying to save HALO.'
Now, five years after the organization was nearly grounded for good, HALO Air Ambulance has doubled its fleet with the addition of a new helicopter.
View image in full screen
HALO-1 is the newest addition to the HALO Air Ambulance fleet of helicopters. Jordan Prentice/Global News
'It's a BK 117, which is the same helicopter we've been flying for years (but) it has bigger engines, so more performance,' said Paul Carolan, CEO of HALO.
Story continues below advertisement
He says being able to move as the crow flies, avoiding roads while cruising at over 250 km/h makes a huge difference when seconds can be vital to saving a life.
'In a perfect world, we would never fly, but that's not the world we live in. We do live in remote and rural Alberta and we don't have all the resources that the big centres have, so this is the way that we can get people where they need to go as quickly as possible,' said Carolan.
The new machine is a serious improvement for HALO, especially when operating in the arid summer conditions around Medicine Hat.
'It doesn't fly any faster or any higher, but in hot temperatures or with heavy loads, it gives us better performance for landing on scene and landing at hospitals.'
It's more than just being an air ambulance, however, as HALO's range also keeps community paramedics in their towns for future emergencies.
'When that call comes in, we can get those advance care paramedics to the person and that has a byproduct of leaving that community paramedic in that community. Now, instead of having a long transport time to Medicine Hat, Lethbridge or Calgary, we land on scene, work with that team, take the patient and get them where they need to go but that paramedic and that ambulance stay in their community. So, if another call comes in, now you still have that resource.'
Story continues below advertisement
The new helicopter is going to take the name of HALO-1, becoming the primary ambulance for the team. Meanwhile, the older HALO-2 will be used as a backup if maintenance is required on HALO-1.
View image in full screen
HALO-2 is the older aircraft with HALO Air Ambulance. Jordan Prentice/Global News
Completing its first emergency call on June 29 in the Bow Island area, HALO-1 has officially entered the service.
'We can be there when the call comes in and truthfully, that's all that matters,' said Carolan.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Global News
4 hours ago
- Global News
Nanaimo considers fencing city hall from overdose prevention site
The City of Nanaimo, B.C., is considering building a 1.8-metre-high fence to protect its staff from 'congregations' of people, violence and disorder associated with an overdose prevention site next to city hall. Staff proposing the $412,000 fence cite 'intimidation and harassment' of employees, particularly those working early or late, as well as damage to staff vehicles, fires near doorways and building perimeters, human waste, and a general deterioration of the site. The plans are outlined in a staff report which says a zoning variance will also be needed to build the 'robust decorative, wrought iron' fence 60 centimetres taller than the permitted 1.2 metres. The report was written in advance of a council committee meeting on Wednesday to approve the project and funding. Mayor Leonard Krog said in an interview Monday that the municipality had a legal obligation to protect its staff and property, and the final costs may be less or more than the recommended budget. Story continues below advertisement 'We can't fence off everybody's private property,' he said. 'We can't control every street, but we do have a duty to our employees, which is legal and present and very clear. This report represents the views of our staff, their feelings, and more importantly, and sadly, their fears and the experience that they have had in the last few years, as we've seen the situation in our streets become the challenge that it is.' City hall and its service and resource centre, or SARC, are near the overdose prevention site funded by Island Health and operated by the Canadian Mental Health Association. It was relocated to Albert Street, next to city hall, in December 2022. Get daily National news Get the day's top news, political, economic, and current affairs headlines, delivered to your inbox once a day. Sign up for daily National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'Since this relocation, the city has experienced a significant increase in disorder around city hall and SARC,' the report says. 'Disorderly behaviour is common both during and outside the facility's hours of operation. When closed, individuals frequently congregate in the parking lots, gardens, and shaded areas around city hall and SARC, leading to considerable safety and operational challenges.' Story continues below advertisement The report says there are 'congregations of 20 to 30+ individuals during early morning and evening hours.' The document recommending the fence, which council has yet to approve, says the area is a 'frequent location for congregations, loitering, violence, and property related concerns, including damage to and theft from staff vehicles, fires, litter, vandalism, and safety risks,' especially for staff accessing the resource centre. It says the overdose prevention site serves a 'highly vulnerable and marginalized population' with many living in extreme poverty, with limited access to health care and support services. It also notes that 'installing fencing around a civic facility may be perceived by some members of the public as a symbol of exclusion, especially in the context of visible homelessness and public disorder in surrounding areas.' A public safety group said the plans should be a 'wake-up call' for provincial and federal leaders to protect 'everyday citizens from those causing mayhem, havoc and violence' on the streets of downtown. Kevan Shaw, vice-president of the Nanaimo Area Public Safety Association, said it was 'horrible, disgusting and sad' that city employees felt scared to come to work, adding that many downtown residents and business owners felt the same. Krog says the situation around city hall was not as 'awful' as the association suggested, but added that he is 'very conscious' of the problems facing downtown. Story continues below advertisement He said he agreed that higher levels of government should act 'not only swiftly, but with far more substance than they have to date.' Krog said he was 'sympathetic' to the frustrations of the association, adding that the city has hired 12 new community safety officers and 15 new RCMP officers during the past five years, with more coming in this year's budget. He said that while the cost of the fencing may be 'offensive' to some, it is unfair to accuse the municipality of leaving residents and business to fend for themselves. 'When you're talking about the amount of area that has to be covered with fencing, I don't think you'll find the cost is extraordinary in comparison to fencing any other area with a fence that would actually be secure when you're allowing for the kind of gating that's necessary.'
Cision Canada
9 hours ago
- Cision Canada
Health Canada Approves Lilly's Omvoh® (mirikizumab) for Crohn's Disease; New Citrate-Free Formulation Français
Omvoh ® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn's disease (CD) In VIVID-1, Omvoh ® showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately to severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. 3 Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, which contains the same active ingredients as the original Omvoh ®. TORONTO, July 15, 2025 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh ® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh ® is an interleukin-23p19 antagonist for the treatment of adult patients with moderately to severely active CD who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment. 1 Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, for the existing UC indication, as well as the new CD indication. "We are pleased to see that Omvoh ® will now be able to provide people living with moderately to severely active CD an effective and safe option for treatment," said Mathilde Merlet, President and General Manager of Lilly Canada. "With this additional indication, we are reinforcing our commitment to helping more of the IBD community. Additionally, we are proud to be able to introduce a new citrate-free formulation, which we hope will improve the patient experience, while offering the same quality, efficacy, and safety that patients are accustomed to." The authorization of Omvoh ® for CD was based on results from the VIVID-1 clinical study, which included over 1,000 adults. In VIVID-1, mirikizumab showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately-to-severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. The coprimary composite endpoints included patient-reported outcome (PRO) clinical response at week 12 and endoscopic response at week 52 (endoscopic response-composite), and PRO clinical response at week 12 and Crohn's Disease Activity Index (CDAI) clinical remission at week 52 (CDAI clinical remission-composite). Endoscopic response-composite was reached in 220 (38%) of 579 patients on mirikizumab versus 18 (9%) of 199 patients on placebo; CDAI clinical remission-composite was reached in 263 (45%) of 579 patients on mirikizumab versus 39 (20%) of 199 patients on placebo. Statistical significance was also observed in subgroups with and without failure to biological therapies for coprimary endpoints and most major secondary endpoints. 3 The Community Reacts: Sylvain Chiasson, Interim President & CEO of Crohn's and Colitis Canada: "Crohn's and Colitis Canada always welcomes new treatments for people with CD in Canada. CD is a chronic autoimmune disease where the immune system attacks the gastrointestinal system. CD is a complex disease that is debilitating, leads to hospitalizations and surgeries, and has a tremendous impact on the quality of life for the approximately 162,000 Canadians living with this disease. Because of the disease's complexity, not all people with CD respond in the same way to the available treatments. So, it is welcome news for Crohn's and Colitis Canada when there is a new therapy available for people with CD." Gail Attara, Chief Executive Officer of the Gastrointestinal Society ( "We are so pleased to learn that Health Canada has approved a CD indication for Omvoh (mirikizumab). Compared to other inflammatory conditions, CD has very few medications, so the introduction of Omvoh's expanded use as a new option is excellent news for the IBD community." Dr. John Marshall, Professor of Medicine, and Director of the Division of Gastroenterology at McMaster University: "It is exciting to see a new and highly effective therapy being made available for people living with CD. Clinical trials have shown mirikizumab to be both safe and effective, and this will be an appealing treatment option for patients who are new to biologic therapies, or those who have not responded adequately to previous advanced therapies." About the VIVID-1 Clinical Trial Program VIVID-1 was a Phase 3, randomized, double-blind, treat-through study that evaluated the safety and efficacy of mirikizumab compared with placebo and an active control (ustekinumab) in adults with moderately to severely active CD. Patients randomized to mirikizumab were administered 900 mg of mirikizumab intravenously every four weeks from Weeks 0-8, then 300 mg subcutaneously every four weeks from Weeks 12-52. In this study, 49% of patients treated with mirikizumab or placebo had experienced a prior biologic failure. 2 The overall safety profile of mirikizumab in patients with moderately to severely active CD was consistent with the known safety profile in patients with UC. The frequency of serious adverse events was greater in placebo than mirikizumab. The most common adverse events were upper respiratory tract infections, injection site reactions, headache, and rash. 1 About Omvoh ® Omvoh ® (mirikizumab) is an interleukin-23p19 (IL-23) antagonist indicated for the treatment of moderately to severely active UC and CD in adults. Omvoh ® selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to overactivation of the IL-23 pathway plays a critical role in the pathogenesis of CD, a chronic, IBD associated with progressive bowel damage, disability and decreased health-related quality of life. For more information about Omvoh ®, please refer to the product monograph on About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. Lilly has been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Lilly's Canadian Affiliate, Eli Lilly Canada Inc. was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially available insulin. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more about Lilly Canada, visit or follow us on LinkedIn. Omvoh ® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Global News
a day ago
- Global News
Alberta surpasses all of the United States in confirmed measles cases
See more sharing options Send this page to someone via email Share this item on Twitter Share this item via WhatsApp Share this item on Facebook Alberta has surpassed the United States in confirmed measles cases, after 30 new cases were diagnosed over the weekend. The province has now seen 1,314 cases since the beginning of March. The U.S. Centers for Disease Control and Prevention has reported 1,288 cases so far this year across 39 states. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy The outbreak of the highly contagious disease hasn't led to any deaths so far in Alberta. Three people, including two children, have died in the United States. The U.S. has also seen more hospitalizations, with the CDC reporting 162 people have been hospitalized compared to just over 100 Albertans. Alberta is home to just under five million people, while the United States population is more than 341 million. Story continues below advertisement — More to come… — With a file from Karen Bartko, Global News
